Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,530
datasets available to search
ShareScore release 0.9.0
Dataset results
3,530 results for “non-small cell lung cancer”
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00083083. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)
ClinicalTrials.gov study NCT03689439. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
ClinicalTrials.gov study NCT04964479. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00030407. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
ClinicalTrials.gov study NCT05788926. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT01051362. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT01514877. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Open the record for dataset details and reuse information.
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
Open the record for dataset details and reuse information.
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A systematic review
<p><b>Objectives:</b> Use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC.</p> <p><b>Design: </b>Systematic review</p> <p><b>Data sources: </b>PubMed, the Cochrane Library, and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library, and World Conference on Lung Cancer for relevant conference abstracts.</p> <p><b>Eligibility criteria: </b>Articles<b> </b>meeting the following<b> </b>criteria were selected: (1) randomized controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously, and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC.</p> <p><b>Data extraction and synthesis:</b> After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs).</p> <p><b>Results:</b> Overall, 10 randomized controlled clinical trials (n = 5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS, and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumor PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18–2.78) and yielded a better OS and PFS when tumor PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC.</p> <p><b>Conclusions:</b> The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumor cells.</p>
Pathological images of non-small cell lung cancer
<p>The dataset comprises lung cancer patient information and pathology images utilized for the analysis of our study. These are anonymized data from cases in our cohort for which patient consent was obtained for public deposition. </p> <p>Patient information for original cohort and validation cohort is described in the Excle files, "original_cohort_patient_info.xlsx" and "validation_cohort_patient_info.xlsx", respectively. </p> <p>These Excel files contain information on sex, age, smoking history, pathological stage, histology, lymphovascular invasion, pleural invasion, lymph node metastasis, adjuvant treatment, survival outcomes and file names for pathological images of each patient. Each patient has two files of Whole Slide Images files (format: .npdi) including hematoxylin & eosin staining ("XXX_h.ndpi") and immunohistochemistry stainig for PD-L1 ("XXX_p.ndpi").</p>
Data from: Downregulation of circATXN7 represses non-small cell lung cancer growth by releasing miR-7-5p
<p>Circular RNAs (circRNAs) participate in the occurrence and progression of many cancers. CircRNA ataxin 7 (circATXN7) (circBase ID: hsa_circ_0066436) plays a promoting influence on gastric cancer progression. However, the biological role of circATXN7 in non-small cell lung cancer (NSCLC) is indistinct. CircATXN7 and PFN2 were highly expressed in NSCLC, whereas miR-7-5p expression had the opposite trend. CircATXN7 overexpression constrained apoptosis and promoted proliferation, metastasis, invasion, and epithelial-mesenchymal transition (EMT) of NSCLC cells, but circATXN7 silencing played the opposing influence and repressed xenograft tumor growth <i>in vivo</i>. CircATXN7 served as a miR-7-5p sponge, and circATXN7 regulated malignant behaviors of NSCLC cells through sponging miR-7-5p. PFN2 acted as a miR-7-5p target. PFN2 silencing overturned the promoting effect of miR-7-5p inhibitor on NSCLC cell malignancy, while PFN2 overexpression reversed the inhibitory impact of miR-7-5p mimic on NSCLC cell malignancy. CircATXN7 accelerated the malignancy of NSCLC cells through adsorbing miR-7-5p and upregulating PFN2, offering evidence to support circATXN7 as a might target for NSCLC treatment.</p>
Datasets accompanying Deep generative AI models analyzing circulating orphan non-coding RNAs enable accurate detection of early-stage non-small cell lung cancer
<p>These datasets accompany the manuscript "Deep generative AI models analyzing circulating orphan non-coding RNAs enable accurate detection of early-stage non-small cell lung cancer".</p> <p>The datasets include:</p> <ul> <li> <p><code>metadata.tsv.gz</code> Phenotype information of the samples</p> </li> <li> <p><code>mirna_counts.tsv.gz</code> MicroRNA count matrix (for data normalization)</p> </li> <li> <p><code>oncrna_counts.tsv.gz</code> oncRNA count matrix</p> </li> <li> <p><code>orion/</code> Ensemble of Orion models</p> </li> </ul>
CircRPPH1 promotes cell proliferation, migration and invasion of non-small cell lung cancer (NSCLC) via the PI3K/AKT and JAK2/STAT3 signaling axes
<p>original numerical data before creating graphs</p>
Figure 5 from: Abbas AH, Mahmood AAR, Tahtamouni LH, Al-Mazaydeh ZA, Rammaha MS, Alsoubani F, Al-bayati RI (2021) A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity. Pharmacia 68(3): 679-692. https://doi.org/10.3897/pharmacia.68.e70654
Figure 5 Compound 5 induces the ER-mediated apoptosis. A) Representative Western blot showing the enhanced release of Smac/DIABLO but not cytochrome c from the mitochondria (MF) into the cytosol (CF) of compound 5-treated A549 lung cancer cells (GI50). Equal protein loading was controlled by staining membranes with Ponceau S (a representative section of the stained membrane is shown). The experiment was repeated three times and the corresponding quantification is shown in (B), B) Quantification of smac/DIABLO and cytochrome C levels in vehicle-treated control A549 cells and cells treated with GI50 amount of compound 5 or 5% DMSO as a negative control. M: mitochondria fraction; C: cytosol fraction. Scale bars: mean ± SEM of three independent experiments. ** p < 0.01 compared to vehicle-treated control cells, C) Representative Western blot showing the induction of phosphorylation of eukaryotic initiation factor-2 (eIF-2) in A549 cells treated with GI50 amounts of compound 5. For comparison purposes, thapsigargin (TG), an ER stress-causing drug was used (3 μM, 2 h) as a positive control. The experiment was repeated three times.
Figure 4 from: Abbas AH, Mahmood AAR, Tahtamouni LH, Al-Mazaydeh ZA, Rammaha MS, Alsoubani F, Al-bayati RI (2021) A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity. Pharmacia 68(3): 679-692. https://doi.org/10.3897/pharmacia.68.e70654
Figure 4 Compound 5 causes caspase activation. A) qRT-PCR analysis of caspase 3, 4, 8 and 9 mRNA in compound 5-treated cells (GI50) as compared to vehicle-treated control cells [set as 1 arbitrary unit (a.u.)]. Values were normalized to β-actin. Scale bars: mean ± SEM of three independent experiments performed in triplicates. *p < 0.05, **p < 0.01 compared to vehicle-treated control cells, B) Representative Western blots showing cleavage "activation' of procaspase 3 to the active form p17, procaspase 4 to the active form p20, and procaspase 9 to the active forms p35/p37. C: vehicle-treated control cells; 0.5%: 0.5% DMSO-treated cells; 1%: 1% DMSO-treated cells; 5%: 5% DMSO-treated cells; C.5: Compound 5-treated cells. The experiment was repeated three times.
Figure 2 from: Abbas AH, Mahmood AAR, Tahtamouni LH, Al-Mazaydeh ZA, Rammaha MS, Alsoubani F, Al-bayati RI (2021) A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity. Pharmacia 68(3): 679-692. https://doi.org/10.3897/pharmacia.68.e70654
Figure 2 The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay results for compound 5 against MCF10A cells, and white blood cells (WBC) after 24, 48 and 72 h of treatment.
Figure 3 from: Abbas AH, Mahmood AAR, Tahtamouni LH, Al-Mazaydeh ZA, Rammaha MS, Alsoubani F, Al-bayati RI (2021) A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity. Pharmacia 68(3): 679-692. https://doi.org/10.3897/pharmacia.68.e70654
Figure 3 Compound 5 induces apoptosis in A549 lung cancer cells. A) Fluorescence images of A549 lung cancer cells showing fragmented nuclei after DAPI staining. Scale bar: 10 µm, B) Detection of DNA fragmentation by agarose gel electrophoresis. Cells were treated and genomic DNA was extracted and electrophoresed on 1.5% agarose gels. M: DNA molecular weight marker; C: vehicle-treated control cells; 1%: 1% DMSO-treated cells; 5%: 5% DMSO-treated cells; C.5: Compound 5-treated cells. Arrows indicate DNA fragments. Three experiments were performed with similar results.
Figure 6 from: Abbas AH, Mahmood AAR, Tahtamouni LH, Al-Mazaydeh ZA, Rammaha MS, Alsoubani F, Al-bayati RI (2021) A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity. Pharmacia 68(3): 679-692. https://doi.org/10.3897/pharmacia.68.e70654
Figure 6 3D View of the target compounds (5, 7A, 6B and 6C) docked against ATP binding site of EGFR kinase.
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00592007. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.